When breakthrough, first-of-their-kind treatments gain approval, the clinical and commercial plans have to be smarter, faster and more flexible. And we think we’re on to something lifechanging for our clients.
Amid a pandemic that has revealed systemic deficiencies, the industry
presses for more diversity in its workforces, research cohorts and communications.